Zosano Pharma Presents Positive Data From Zotrip Study

Zosano Pharma presented data on Saturday from its phase 2/3 Zotrip study for the acute treatment of migraines during the annual meeting of the American Headache Society in Boston.

Data showed that the 3.8mg dose of M207 achieved both co-primary endpoints of pain freedom and most bothersome symptom freedom at 2 hours. In addition, the 3.8mg dose achieved significance in the secondary endpoints of pain freedom at 45 minutes and 1 hour and showed durability of effect on pain freedom at 24 and 48 hours. In post-hoc analyses, M207 also demonstrated efficacy in traditionally difficult to treat established migraine headaches.

Leave a Comment